Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850056831826657280 |
|---|---|
| author | Bilal Kazi Imaan Rumani Marzooka Nazim Chishti Kazi Prashant Manohar Gaikwad |
| author_facet | Bilal Kazi Imaan Rumani Marzooka Nazim Chishti Kazi Prashant Manohar Gaikwad |
| author_sort | Bilal Kazi |
| collection | DOAJ |
| description | Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications. |
| format | Article |
| id | doaj-art-72d98a96e6fd4094b1dae4d86925166a |
| institution | DOAJ |
| issn | 2666-6219 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Problems in Cancer: Case Reports |
| spelling | doaj-art-72d98a96e6fd4094b1dae4d86925166a2025-08-20T02:51:35ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192025-03-011710034510.1016/j.cpccr.2024.100345Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic riskBilal Kazi0Imaan Rumani1Marzooka Nazim Chishti Kazi2Prashant Manohar Gaikwad3SUNACT Cancer Institute. Department of Hematology, Bone Marrow Transplantation and Cellular therapy, Tietan Medicity Hospital, Kasarvadavali, Thane, 400615, Maharashtra, India; Corresponding author.SUNACT Cancer Institute. Department of Oncosurgery, Tietan Medicity Hospital, Kasarvadavali, Thane, 400615, Maharashtra, IndiaDepartment of Pharmaceutics. Y.B Chavhan College of Pharmacy. Aurangabad, IndiaDepartment of endocrinology, MGM Medical College and Hospital, Navi Mumbai, IndiaOlanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications.http://www.sciencedirect.com/science/article/pii/S2666621924000668Olanzapine (Zyprexa)NauseaHypertriglyceridemiaDyslipidemia |
| spellingShingle | Bilal Kazi Imaan Rumani Marzooka Nazim Chishti Kazi Prashant Manohar Gaikwad Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk Current Problems in Cancer: Case Reports Olanzapine (Zyprexa) Nausea Hypertriglyceridemia Dyslipidemia |
| title | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| title_full | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| title_fullStr | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| title_full_unstemmed | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| title_short | Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk |
| title_sort | olanzapine induced hypertriglyceridemia in cancer care a silent metabolic risk |
| topic | Olanzapine (Zyprexa) Nausea Hypertriglyceridemia Dyslipidemia |
| url | http://www.sciencedirect.com/science/article/pii/S2666621924000668 |
| work_keys_str_mv | AT bilalkazi olanzapineinducedhypertriglyceridemiaincancercareasilentmetabolicrisk AT imaanrumani olanzapineinducedhypertriglyceridemiaincancercareasilentmetabolicrisk AT marzookanazimchishtikazi olanzapineinducedhypertriglyceridemiaincancercareasilentmetabolicrisk AT prashantmanohargaikwad olanzapineinducedhypertriglyceridemiaincancercareasilentmetabolicrisk |